AC Immune SA Announces Results Of Annual General Meeting

AC Immune Announces Results of Annual General Meeting
  • Financial expert Mr. Thomas Graney elected as new member of the Board of Directors
  • Shareholders approve all proposed resolutions of the board of directors

LAUSANNE, Switzerland, Nov. 15, 2016 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the company have elected Mr. Thomas Graney as a new member of the Board of Directors of the Company at its Annual General Meeting held at EPFL Innovation Park, Lausanne.

Martin Velasco, Chairman of the Board of Directors of AC Immune, commented, "We are very pleased to welcome Tom Graney to our Board of Directors, the Compensation, Nomination and Corporate Governance Committee and the Finance and Audit Committee. His experience in corporate finance and international business and development will bring great expertise and experience to our Board. This comes at the right time as we transition AC Immune into a publicly traded company and continue to develop our strong pipeline of therapeutics and diagnostics targeting neurodegenerative disorders."

The shareholders of the company also approved all other resolutions proposed. The detailed resolutions are available on the  company's website.Furthermore, AC Immune confirms that Dr. Mathias Hothum has retired from the Board at the conclusion of the Annual General Meeting.

About Mr. Tom Graney Mr. Graney serves as Chief Financial Officer and Senior Vice President of Finance & Corporate Strategy at Ironwood Pharmaceuticals, Inc., a post held since September 2014. Prior to Ironwood his professional career included 20 years with Johnson & Johnson and its affiliates, serving for four years as Worldwide Vice President of Finance and Chief Financial Officer of Ethicon, a Johnson & Johnson company. In addition, Mr. Graney has extensive global experience spanning corporate development, commercial strategy, portfolio management and supply chain management. Mr. Graney is a Chartered Financial Analyst charterholder and holds a B.S. in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.

If you liked this article you might like

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know